Browse the corpus

Ifosfamide, an alkylating agent and a cyclophosphamide analog, is used as a single agent or in combination with other drugs to treat various types of cancer. Ifosfamide is a cytotoxic, antineoplastic medication used to manage and treat diverse cancers, including lymphoma, sarcoma, and lung cancer. This activity outlines the indications, administration procedures, and contraindications for ifosfamide, highlighting its significance as a valuable agent in treating various cancers. This activity also reviews the mechanism of action, adverse event profile, pharmacodynamics, pharmacokinetics, monitoring, and relevant interactions of ifosfamide. This information is pertinent for the interprofessional healthcare team involved in the comprehensive management of malignancies and related conditions in patients. Objectives: Identify the appropriate indications for ifosfamide, recognizing its role as a cytotoxic, antineoplastic agent to treat various malignancies, including lymphoma, sarcoma, and lung cancer. Implement safe and effective administration procedures for ifosfamide, considering dosing, infusion rates, and concurrent medications. Assess patients for potential adverse events, particularly focusing on hemorrhagic cystitis, neurotoxicity, and myelosuppression, and initiate appropriate management strategies. Collaborate among interprofessional healthcare teams, including pharmacists, nurses, and oncologists, to integrate ifosfamide into targeted therapeutic regimens, emphasizing a patient-centered approach for enhanced care outcomes. Access free multiple choice questions on this topic.

Most of the ifosfamide toxicity is due to its active metabolites. Acrolein, in particular, significantly contributes to major renal and bladder-related toxicity. As the kidneys filter these metabolites, they generate ROS and nitrogen compounds that damage the renal and urothelial cells. The etiology of neurotoxicity is similar to renal toxicity but is not fully understood. As with other antineoplastic drugs, ifosfamide is toxic to bone marrow. Additional toxicities associated with ifosfamide are mentioned below. Hemorrhagic Cystitis Before the availability of mesna, the main adverse effect was hemorrhagic cystitis. This is due to hepatic metabolism producing acrolein, which is excreted by the kidneys and accumulates in the bladder.[30] The apoptotic properties of acrolein, along with its production of multiple ROS and nitric oxide, lead to the release of numerous cytokines, causing ulceration of the bladder epithelium and resulting in hemorrhagic cystitis. Mesna, developed in 1983, was specifically designed to address this adverse effect associated with ifosfamide. As described earlier, mesna combines with the urotoxic metabolites at the urothelial level, forming a nontoxic product for excretion in the urine. Notably, it is crucial to aim to prevent the development of cystitis rather than address it after onset. The current treatment options are continuous bladder irrigation, intravesicular infusion of ammonium potassium sulfate and formalin, and, in some instances, cystectomy.[30] Mesna administration is recommended before, during, and after ifosfamide treatment, accompanied by aggressive hydration of at least 2 L—oral or intravenous to prevent urotoxicity. Neurotoxicity Central nervous system toxicity manifests as encephalopathy with varying severity, presenting symptoms such as confusion, hallucinations, drowsiness, and, in severe cases, coma. This occurs in approximately 30% of cases, with symptoms more prominent during the administration of high doses, particularly through oral administration.[36] Usually, the symptoms present within 2 to 96 hours after drug administration and are reversible within 48 to 72 hours following discontinuation of the drug.[17] Risk factors associated with the development of neurotoxicity include oral administration, previous chemotherapy with cisplatin, impaired renal and hepatic function, low albumin, and brain metastasis.

Central nervous system toxicity manifests as encephalopathy with varying severity, presenting symptoms such as confusion, hallucinations, drowsiness, and, in severe cases, coma. This occurs in approximately 30% of cases, with symptoms more prominent during the administration of high doses, particularly through oral administration.[36] Usually, the symptoms present within 2 to 96 hours after drug administration and are reversible within 48 to 72 hours following discontinuation of the drug.[17] Risk factors associated with the development of neurotoxicity include oral administration, previous chemotherapy with cisplatin, impaired renal and hepatic function, low albumin, and brain metastasis. Methylene blue can be used for the treatment and prophylaxis of ifosfamide-induced encephalopathy (IIE) due to its ability to inhibit the formation of neurotoxic metabolites associated with this condition.[37] Administration of methylene blue has been shown to reverse symptoms within 24 hours. The recommended dosage is 50 mg orally in a 5% glucose solution every 4 hours until recovery.[17] As a prophylactic measure, methylene blue can mitigate the severity of symptoms compared to previous cycles, allowing the resumption of ifosfamide therapy. The recommended prophylactic dose is 50 mg IV every 6 to 8 hours during ifosfamide administration. Prescribers should exercise caution regarding the potential for serotonin syndrome with methylene blue, especially when the patient is concurrently prescribed serotoninergic medications.[38] Hematologic Toxicity Myelosuppression is a dose-limiting toxicity, with blood counts reaching their nadir approximately 8 to 13 days into the treatment cycle. Recovery typically occurs around day 17 of the treatment cycle, allowing for the commencement of the next cycle approximately 3 weeks after the first treatment. The incidence of myelosuppression is lower when fractionated doses are used instead of higher doses.[39] At a dosage of 1.2 g/m²/d for 5 days, around 30% of cases experience a white cell count below 3×109/L and a platelet count below 20,000/μL.[39] According to the joint American Society of Clinical Oncology (ASCO)/Infectious Diseases Society of America (IDSA) guideline, patients receiving ifosfamide at doses >9 g/m² are at a higher risk for febrile neutropenia.[40] Nephrotoxicity

Myelosuppression is a dose-limiting toxicity, with blood counts reaching their nadir approximately 8 to 13 days into the treatment cycle. Recovery typically occurs around day 17 of the treatment cycle, allowing for the commencement of the next cycle approximately 3 weeks after the first treatment. The incidence of myelosuppression is lower when fractionated doses are used instead of higher doses.[39] At a dosage of 1.2 g/m²/d for 5 days, around 30% of cases experience a white cell count below 3×109/L and a platelet count below 20,000/μL.[39] According to the joint American Society of Clinical Oncology (ASCO)/Infectious Diseases Society of America (IDSA) guideline, patients receiving ifosfamide at doses >9 g/m² are at a higher risk for febrile neutropenia.[40] Nephrotoxicity Nephrotoxicity is most commonly observed in children, particularly when ifosfamide is coadministered with cisplatin. This combination can lead to Fanconi syndrome, impairing proximal tubule function and causing irreversible damage. Fanconi syndrome presents with metabolic acidosis, polyuria, and renal phosphate wasting, occurring in approximately 5% of cases. Furthermore, providing vitamin D and phosphate supplementation is crucial to address these effects in the affected pediatric population.[41] According to the Kidney Disease Improving Global Outcomes (KDIGO) guidelines, ifosfamide-induced nephrotoxicity is attributed to its mechanism of inhibiting DNA synthesis. This inhibition leads to DNA strand–breaking effects, culminating in acute tubular injury and necrosis.[42] Miscellaneous Toxicities Other toxicities, including arrhythmias, heart failure, and pulmonary toxicity in the form of pneumonitis, have been reported.[43] Ureter and Bladder Malignancies Multifocal urothelial carcinoma has been reported in patients treated with ifosfamide several years ago.[15]

The administration and monitoring of chemotherapy drugs, including ifosfamide, are crucial in nursing and pharmacy. Effective collaboration among all healthcare providers within an interprofessional team is essential to ensure optimal care and minimize the adverse effects of chemotherapeutic agents. Nursing staff are crucial in closely monitoring patients during and after drug administration, identifying adverse reactions, and promptly reporting them. With specialized training in chemotherapy administration, oncology nurses contribute significantly to ensuring patient safety and well-being. Pharmacists help formulate and monitor dosing to prevent potential toxicity. The collaboration between nurses and pharmacists is essential for providing patient counseling about the drug, including expectations following administration and throughout the treatment cycles. A study conducted to integrate nurse practitioners, physician assistants, and pharmacists as limited oncology practice providers (LOPPs) within an academic medical center aimed to evaluate the implementation of a privileging process for these healthcare professionals. The results indicated a positive influence of LOPPs on oncology practice, with oncologists and advanced practice providers reporting beneficial outcomes.[44] An interprofessional healthcare team is crucial for optimizing ifosfamide therapy outcomes through effective communication and coordination.